| Bioactivity | DSS30 is a P25/CDK5 inhibitor that reduces β-amyloid (Aβ) secretion by inhibiting amyloid precursor protein lyase 1 (BACEl) phosphorylation. DSS30 can be used in the study of neurodegenerative diseases such as Alzheimer's disease[1]. |
| Invitro | DSS30 (50 μM, 2 hours) inhibits the activity of the P25/CDK5 complex by up to 50% and the phosphorylation of BACE1 or Tau[1]. Western Blot Analysis[1] Cell Line: |
| Name | DSS30 |
| CAS | 883027-32-5 |
| Formula | C16H14ClNO3S2 |
| Molar Mass | 367.87 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Sul-Hee Chung, et al. Pharmaceutical composition comprising a p25/cdk5 inhibitor for preventing or treating a neurodegenerative disease. WO2006075808 |